Cargando…

Improving cancer immunotherapy by targeting IL-1

Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Zhilan, Singh, Shubhra, Singh, Manisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632280/ https://www.ncbi.nlm.nih.gov/pubmed/34858734 http://dx.doi.org/10.1080/2162402X.2021.2008111

Ejemplares similares

Targeting inflammasome/IL-1 pathways for cancer immunotherapy
por: Guo, Beichu, et al.
Publicado: (2016)

IL‐1β Is an Androgen‐Responsive Target in Macrophages for Immunotherapy of Prostate Cancer
por: Wang, Deng, et al.
Publicado: (2023)

Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
por: Kim, Ji-Hae, et al.
Publicado: (2021)

IL-1RN and IL-1β Polymorphism and ARV-Associated Hepatotoxicity
por: Singh, HariOm, et al.
Publicado: (2018)

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
por: Lazear, Eric, et al.
Publicado: (2017)

Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
por: Ghasemi, Reza, et al.
Publicado: (2016)

Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15
por: Müller, Dafne
Publicado: (2012)

New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
por: Soler, Maria Florencia, et al.
Publicado: (2023)

IL-2 immunotherapy for targeting regulatory T cells in autoimmunity
por: Lykhopiy, Valentina, et al.
Publicado: (2023)

Prospects of IL-2 in Cancer Immunotherapy
por: Choudhry, Hani, et al.
Publicado: (2018)

Heterodimeric IL-15 in Cancer Immunotherapy
por: Bergamaschi, Cristina, et al.
Publicado: (2021)

IL-15 in the Combination Immunotherapy of Cancer
por: Waldmann, Thomas A., et al.
Publicado: (2020)

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014)

Improving cancer immunotherapy by targeting the STATe of MDSCs
por: de Haas, Nienke, et al.
Publicado: (2016)

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
por: Le Bourgeois, Thibault, et al.
Publicado: (2018)

Comparative Roles of IL-1, IL-6, IL-10, IL-17, IL-18, 1L-22, IL-33, and IL-37 in Various Cardiovascular Diseases With Potential Insights for Targeted Immunotherapy
por: Abubakar, Muhammad, et al.
Publicado: (2023)

Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
por: Huppler, Anna R, et al.
Publicado: (2012)

Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy
por: Xiao, Chu, et al.
Publicado: (2022)

Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
por: Yang, Ying, et al.
Publicado: (2020)

The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy
por: Wang, Chunli, et al.
Publicado: (2022)

Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
por: Yang, Fan, et al.
Publicado: (2021)

Immunotherapy: The future of cancer treatment
por: Sahu, Manisha, et al.
Publicado: (2021)

IL-12 Family Cytokines in Cancer and Immunotherapy
por: Mirlekar, Bhalchandra, et al.
Publicado: (2021)

Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy
por: Hu, Qiyue, et al.
Publicado: (2018)

Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2
por: Horton, Brendan L., et al.
Publicado: (2023)

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
por: Bhatia, Vipul, et al.
Publicado: (2023)

Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy
por: Kawakami, Yutaka, et al.
Publicado: (2013)

Emerging Prevention and Treatment Strategies to Control COVID-19
por: Singh, Vipul K., et al.
Publicado: (2020)

The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression
por: Zhang, Zhilan, et al.
Publicado: (2020)

Dual Roles of IL-27 in Cancer Biology and Immunotherapy
por: Fabbi, Marina, et al.
Publicado: (2017)

Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes
por: Baeyens, Audrey, et al.
Publicado: (2013)

Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges
por: Noman, Muhammad Zaeem, et al.
Publicado: (2019)

Targeting Metabolic Pathways of Myeloid Cells Improves Cancer Immunotherapy
por: Li, Jianying, et al.
Publicado: (2021)

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
por: Hirayama, Alexandre V., et al.
Publicado: (2022)

Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment
por: Wei, Jinfen, et al.
Publicado: (2022)

The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
por: Janji, Bassam, et al.
Publicado: (2022)

Systems Biology and Cytokines Potential Role in Lung Cancer Immunotherapy Targeting Autophagic Axis
por: Khilwani, Riya, et al.
Publicado: (2023)

Advancements in Cancer Immunotherapies
por: Roy, Ruchi, et al.
Publicado: (2022)

Folate-Targeted mRNA Delivery Using Chitosan-Functionalized Selenium Nanoparticles: Potential in Cancer Immunotherapy
por: Maiyo, Fiona, et al.
Publicado: (2019)

IL-18BP is decreased in osteoporotic women: Prevents Inflammasome mediated IL-18 activation and reduces Th17 differentiation
por: Mansoori, Mohd Nizam, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uhp899m6mris8lqnhkt24vcui8